
Chinese pharmaceutical company established on 16 September 1996 at 789 Lanmao Road in the Majinpu subdistrict of the Kunming High-tech Zone, Yunnan, with registered capital of about 400.5 million yuan and listed on the Shenzhen Stock Exchange main board on 24 March 2015 under code 002750. Researches, manufactures and sells modern traditional Chinese medicines and specialty chemical generics focused on cardio-cerebrovascular and endocrine disease. Its flagship product, breviscapine for injection, is a single component preparation of scutellarin with purity above ninety-eight per cent covered by close to twenty invention patents, and the company has been named among Yunnan's top hundred private enterprises, a provincial strategic emerging industry leader and an intelligent manufacturing demonstration enterprise.
평가 남기기